NovelCath

NovelCath is dedicated to designing and manufacturing advanced catheter delivery systems for minimally invasive medical procedures, focusing on structural heart, electrophysiology, and neurovascular applications. Founded in 2019 and headquartered in Minneapolis, US, NovelCath develops catheter systems tailored for various medical procedures. The company was acquired by Cirtec Medical Corp. in December 2020.

This acquisition marked a significant strategic shift for NovelCath as it integrated into a larger portfolio focused on medical device innovations. The founder's previous ventures are not specified. NovelCath specializes in the design, development, and manufacturing of highly engineered catheter delivery systems tailored for minimally invasive interventional applications. Their core offerings encompass a range of products designed for structural heart, electrophysiology, and neurovascular procedures.

These catheter systems integrate advanced technologies such as steerable and multi-directional catheter shafts, achieving optimal performance in complex medical environments. The company serves a diverse client base, including hospitals, medical device companies, and healthcare providers within the United States and internationally across Europe and Asia. NovelCath’s commitment to innovation is underscored by its support of early-stage development programs, offering design consultation and rapid prototyping to ensure manufacturability and efficacy in real-world applications. NovelCath operates primarily on a business-to-business (B2B) transaction model, collaborating directly with medical device companies and healthcare institutions to provide custom catheter solutions.

Revenue is generated through contracts for tailored catheter systems, which may include extensive design and manufacturing services. The company engages in structured agreements encompassing partnerships for product development, as well as volume-based contracts ensuring steady supply to clients. Through these transactions, NovelCath delivers specific catheter designs that meet the unique clinical needs of its customers, solidifying its role as a key provider in the minimally invasive medical device market. While detailed pricing structures are proprietary, the transactions reflect the advanced engineering and specialized capabilities embedded in their flagship products.

NovelCath aims to expand its product offerings with new catheter systems targeting advanced minimally invasive applications, although specific launch dates are not disclosed. The company is also looking into expanding its market presence into Europe and Asia by the end of 2023. The recent acquisition by Cirtec Medical Corp. will support these initiatives by providing additional resources and expertise to enhance product development and market penetration.

The most recent deal was finalized on December 17, 2020, marking a pivotal moment in NovelCath's growth trajectory.